The Phase Ib/II trial assessed evorpacept plus zanidatamab in previously treated, metastatic HER2-expressing cancers.

If you're curious about how to hand express breast milk for your baby, look no further! We turned to the experts to learn everything you need to know. Aliseenko/Getty Images Medically reviewed by ...

"Among the patients with matched samples from breast primary and metastatic sites in this study, there was a significant level of discordance in HER2 expression." — Megan Kruse, MD A team from the ...

New data from a phase 1b/2 clinical trial shows that a specific protein called CD47 can help predict how well the investigational drug evorpacept works for patients with metastatic breast cancer, ALX ...

Optimal management recommendations for patients with HER2 low breast cancer are unclear/unknown. Patients with HER2-low tumors in the new study accounted for more than half of all early breast cancer ...

- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full ...

CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising ...

Considering the paucity of discussion in the literature, it appears that the implications of expressing on maternal mental health warrants attention. Identify relationships between breast pump use and ...